Because there are no selective HDAC4 inhibitors, we decided to work with NaBut, an HDAC pan-inhibitor that easily penetrates the blood–brain barrier and that has shown potential in several neurodegenerative diseases and models (Chuang et al., 2009), administered systemically. This evidence concerns the gene HDAC9 and neurodegenerative disease.